The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer

Yoon Ji Choi, Won Jin Chang, Sang Won Shin, Kyong Hwa Park, Seung Tae Kim, Yeul Hong Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: C-X-C chemokine receptor type 4 (CXCR4) is involved in tumor progression including angiogenesis, metastasis, and survival. However, whether serum CXCR4 levels in metastatic or recurrent colorectal cancer have a prognostic role, have not been evaluated. Methods: We analyzed serum samples from 55 patients with advanced colorectal cancer diagnosed between March 2008 and July 2011. Serum CXCR4 levels were quantified by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results: The median age of the patients was 62 years, and all patients received systemic chemotherapy of two or more lines. The median serum CXCR4 level was 283.47 pg/mL (range:77.48-846.52). Patients with two or more metastatic sites, liver metastasis, or higher CA 19-9 level (>37 IU/mL) showed significantly higher levels of serum CXCR4 than patients without. The median overall survival (OS) of all patients was 19.53 months. OS was significantly longer in patients with lower CXCR4 levels (≤240.45 pg/mL) compared with those having higher CXCR4 levels (>240.45 pg/mL) (median OS: 26.50 vs 17.03 months, P=0.046). Univariate analysis showed that liver metastasis, no palliative surgery, and higher levels of CXCR4 (>240.45 pg/mL) had a significantly poor prognostic value with regard to OS (P

Original languageEnglish
Pages (from-to)3307-3312
Number of pages6
JournalOncoTargets and Therapy
Volume9
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

CXC Chemokines
Chemokine Receptors
Colorectal Neoplasms
Serum
Survival
Neoplasm Metastasis
Liver
Palliative Care
Enzyme-Linked Immunosorbent Assay
Drug Therapy

Keywords

  • Colorectal cancer
  • CXCR4
  • Overall survival
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{ac159c6dedd8455b8d84d00c7b9babb9,
title = "The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer",
abstract = "Background: C-X-C chemokine receptor type 4 (CXCR4) is involved in tumor progression including angiogenesis, metastasis, and survival. However, whether serum CXCR4 levels in metastatic or recurrent colorectal cancer have a prognostic role, have not been evaluated. Methods: We analyzed serum samples from 55 patients with advanced colorectal cancer diagnosed between March 2008 and July 2011. Serum CXCR4 levels were quantified by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results: The median age of the patients was 62 years, and all patients received systemic chemotherapy of two or more lines. The median serum CXCR4 level was 283.47 pg/mL (range:77.48-846.52). Patients with two or more metastatic sites, liver metastasis, or higher CA 19-9 level (>37 IU/mL) showed significantly higher levels of serum CXCR4 than patients without. The median overall survival (OS) of all patients was 19.53 months. OS was significantly longer in patients with lower CXCR4 levels (≤240.45 pg/mL) compared with those having higher CXCR4 levels (>240.45 pg/mL) (median OS: 26.50 vs 17.03 months, P=0.046). Univariate analysis showed that liver metastasis, no palliative surgery, and higher levels of CXCR4 (>240.45 pg/mL) had a significantly poor prognostic value with regard to OS (P",
keywords = "Colorectal cancer, CXCR4, Overall survival, Prognosis",
author = "Choi, {Yoon Ji} and Chang, {Won Jin} and Shin, {Sang Won} and Park, {Kyong Hwa} and Kim, {Seung Tae} and Kim, {Yeul Hong}",
year = "2016",
month = "6",
day = "1",
doi = "10.2147/OTT.S104511",
language = "English",
volume = "9",
pages = "3307--3312",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer

AU - Choi, Yoon Ji

AU - Chang, Won Jin

AU - Shin, Sang Won

AU - Park, Kyong Hwa

AU - Kim, Seung Tae

AU - Kim, Yeul Hong

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: C-X-C chemokine receptor type 4 (CXCR4) is involved in tumor progression including angiogenesis, metastasis, and survival. However, whether serum CXCR4 levels in metastatic or recurrent colorectal cancer have a prognostic role, have not been evaluated. Methods: We analyzed serum samples from 55 patients with advanced colorectal cancer diagnosed between March 2008 and July 2011. Serum CXCR4 levels were quantified by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results: The median age of the patients was 62 years, and all patients received systemic chemotherapy of two or more lines. The median serum CXCR4 level was 283.47 pg/mL (range:77.48-846.52). Patients with two or more metastatic sites, liver metastasis, or higher CA 19-9 level (>37 IU/mL) showed significantly higher levels of serum CXCR4 than patients without. The median overall survival (OS) of all patients was 19.53 months. OS was significantly longer in patients with lower CXCR4 levels (≤240.45 pg/mL) compared with those having higher CXCR4 levels (>240.45 pg/mL) (median OS: 26.50 vs 17.03 months, P=0.046). Univariate analysis showed that liver metastasis, no palliative surgery, and higher levels of CXCR4 (>240.45 pg/mL) had a significantly poor prognostic value with regard to OS (P

AB - Background: C-X-C chemokine receptor type 4 (CXCR4) is involved in tumor progression including angiogenesis, metastasis, and survival. However, whether serum CXCR4 levels in metastatic or recurrent colorectal cancer have a prognostic role, have not been evaluated. Methods: We analyzed serum samples from 55 patients with advanced colorectal cancer diagnosed between March 2008 and July 2011. Serum CXCR4 levels were quantified by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results: The median age of the patients was 62 years, and all patients received systemic chemotherapy of two or more lines. The median serum CXCR4 level was 283.47 pg/mL (range:77.48-846.52). Patients with two or more metastatic sites, liver metastasis, or higher CA 19-9 level (>37 IU/mL) showed significantly higher levels of serum CXCR4 than patients without. The median overall survival (OS) of all patients was 19.53 months. OS was significantly longer in patients with lower CXCR4 levels (≤240.45 pg/mL) compared with those having higher CXCR4 levels (>240.45 pg/mL) (median OS: 26.50 vs 17.03 months, P=0.046). Univariate analysis showed that liver metastasis, no palliative surgery, and higher levels of CXCR4 (>240.45 pg/mL) had a significantly poor prognostic value with regard to OS (P

KW - Colorectal cancer

KW - CXCR4

KW - Overall survival

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84973129808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973129808&partnerID=8YFLogxK

U2 - 10.2147/OTT.S104511

DO - 10.2147/OTT.S104511

M3 - Article

VL - 9

SP - 3307

EP - 3312

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -